{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:03:36Z","timestamp":1788476616021,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11912-023-01425-1","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T03:02:35Z","timestamp":1684724555000},"page":"897-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Immunotherapy in Head and Neck Cancer: Where Do We Stand?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-5393","authenticated-orcid":false,"given":"Natalia G.","family":"Vallianou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Kounatidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotis","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Geladari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Karampela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Stratigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"1425_CR1","doi-asserted-by":"publisher","unstructured":"Vos T, Abajobir AA, Abate KH; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390:1211\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2.","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"1425_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1425_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1425_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41415-022-5166-x","volume":"233","author":"M Gormley","year":"2022","unstructured":"Gormley M, Creaney G, Schasche A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dental J. 2022;233(9):780\u20136. https:\/\/doi.org\/10.1038\/s41415-022-5166-x.","journal-title":"Br Dental J"},{"key":"1425_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"key":"1425_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"Global Burden of Disease Cancer Collaboration","year":"2017","unstructured":"Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524\u201348. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688.","journal-title":"JAMA Oncol"},{"key":"1425_CR7","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","volume":"33","author":"ML Gillison","year":"2015","unstructured":"Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235\u201342. https:\/\/doi.org\/10.1200\/JCO.2015.61.6995.","journal-title":"J Clin Oncol"},{"key":"1425_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000485322","volume":"94","author":"S Yete","year":"2018","unstructured":"Yete S, D\u2019Souza W, Saranath D. High-risk human papillomavirus in oral cancer: clinical implications. Oncology. 2018;94:133\u201341. https:\/\/doi.org\/10.1159\/000485322.","journal-title":"Oncology"},{"key":"1425_CR9","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294\u2013301. https:\/\/doi.org\/10.1200\/JCO.2011.36.4596.","journal-title":"J Clin Oncol"},{"key":"1425_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/postgradmedj-2016-134603","volume":"93","author":"A Shah","year":"2017","unstructured":"Shah A, Malik A, Garg A, Mair M, Nair S, Chaturvedi P. Oral sex and human papilloma virus-related head and neck squamous cell cancer: a review of the literature. Postgrad Med J. 2017;93:704\u20139. https:\/\/doi.org\/10.1136\/postgradmedj-2016-134603.","journal-title":"Postgrad Med J"},{"key":"1425_CR11","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/nejm011610","volume":"345","author":"YC Chien","year":"2001","unstructured":"Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen C, Yang CS. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345:1877\u201382. https:\/\/doi.org\/10.1056\/nejm011610.","journal-title":"N Engl J Med"},{"key":"1425_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/00130404-200503000-00002","volume":"11","author":"EM Sturgis","year":"2005","unstructured":"Sturgis EM, Pytynia KB. After the smoke clears: environmental and occupational risks for carcinoma of the upper aerodigestive tract. Cancer J. 2005;11:96\u2013103. https:\/\/doi.org\/10.1097\/00130404-200503000-00002.","journal-title":"Cancer J"},{"key":"1425_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra171571","volume":"382","author":"LQM Chow","year":"2020","unstructured":"\u2022\u2022 Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60\u201372. https:\/\/doi.org\/10.1056\/NEJMra171571. An expert\u2019s opinion on the pathogenesis and treatment options regarding head and neck cancer.","journal-title":"N Engl J Med"},{"key":"1425_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1056\/NEJM199301213280306","volume":"328","author":"EE Vokes","year":"1993","unstructured":"Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184\u201394. https:\/\/doi.org\/10.1056\/NEJM199301213280306.","journal-title":"N Engl J Med"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.oraloncology.2013.01.005","volume":"49","author":"F Peyrade","year":"2013","unstructured":"Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol. 2013;49:482\u201391. https:\/\/doi.org\/10.1016\/j.oraloncology.2013.01.005.","journal-title":"Oral Oncol"},{"key":"1425_CR16","doi-asserted-by":"publisher","first-page":"103679","DOI":"10.1016\/j.critrevonc.2022.103679","volume":"174","author":"M Fasano","year":"2022","unstructured":"Fasano M, Corte CMD, Liello RD, Viscardi G, Sparano F, Iacovino ML, Paragliola F, Piccolo A, Napolitano S, Martini G, Morgillo F, Cappabianca S, Ciardiello F. Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol. 2022;174:103679. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103679.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1425_CR17","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3390\/biomedicines10092151","volume":"10","author":"D Pereiera","year":"2022","unstructured":"\u2022 Pereiera D, Martins D, Mendes F. Immunotherapy in head and neck cancer: when, how and why? Biomedicines. 2022;10:2151. https:\/\/doi.org\/10.3390\/biomedicines10092151. A review article elaborating \u03bf\u03bd immunotherapy in R\/MHNSCC.","journal-title":"Biomedicines"},{"key":"1425_CR18","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3390\/cancers150300852","volume":"15","author":"R Chakraborty","year":"2023","unstructured":"Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and neck cancer immunotherapy: molecular biological aspectsof preclinical and clinical research. Cancers. 2023;15:852. https:\/\/doi.org\/10.3390\/cancers150300852.","journal-title":"Cancers"},{"key":"1425_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.semcancer.2021.05.008","volume":"73","author":"N Spyrou","year":"2021","unstructured":"Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune checkpoint inhibitors therapy era. Semin Cancer Biol. 2021;73:356\u201376. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.008.","journal-title":"Semin Cancer Biol"},{"key":"1425_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","volume":"10","author":"WB Coley","year":"1893","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;10:487\u2013511.","journal-title":"Am J Med Sci"},{"issue":"4","key":"1425_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/toxins12040241","volume":"12","author":"RD Carlson","year":"2020","unstructured":"Carlson RD, Flickinger JC, Snook AE. Talkin\u2019 Toxin\u2019s From Coley\u2019s to modern cancer immunotherapy. Toxins. 2020;12(4):241. https:\/\/doi.org\/10.3390\/toxins12040241.","journal-title":"Toxins"},{"key":"1425_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1988","unstructured":"Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin family-CTLA-4. Nature. 1988;328:267\u201370.","journal-title":"Nature"},{"issue":"22","key":"1425_CR23","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG. Ipilimimab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1595.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1425_CR24","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cells9061376","volume":"9","author":"Y Ishida","year":"2020","unstructured":"Ishida Y. PD-1: its discovery, involvement in cancer immunotherapy and beyond. Cells. 2020;9(6):1376. https:\/\/doi.org\/10.3390\/cells9061376.","journal-title":"Cells"},{"key":"1425_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","volume":"119","author":"R Mehra","year":"2018","unstructured":"Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153\u20139. https:\/\/doi.org\/10.1038\/s41416-018-0131-9.","journal-title":"Br J Cancer"},{"key":"1425_CR26","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase ii study. J Clin Oncol. 2017;35:1542\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.70.1524.","journal-title":"J Clin Oncol"},{"key":"1425_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. KEYNOTE-048 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8.","journal-title":"Lancet"},{"key":"1425_CR28","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"key":"1425_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184. https:\/\/doi.org\/10.1186\/s40425-019-0662-5.","journal-title":"J Immunother Cancer"},{"key":"1425_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","volume":"107","author":"DP Zandberg","year":"2019","unstructured":"Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Bra\u00f1a I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mes\u00eda R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.015.","journal-title":"Eur J Cancer"},{"key":"1425_CR31","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","volume":"29","author":"AD Colevas","year":"2018","unstructured":"Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fasso M, O\u2019Hear C, Powderly J. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29:2247\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdy411.","journal-title":"Ann Oncol"},{"key":"1425_CR32","doi-asserted-by":"publisher","first-page":"e002998","DOI":"10.1136\/jitc-2021-002998","volume":"9","author":"J Guigay","year":"2021","unstructured":"Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, Gordon MS, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Sch\u00f6ffski P, Grote HJ, Zhou D, Bajars M, Penel N. Avelumab for platinum-ineligible\/refractory recurrent and\/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN solid tumor trial. J Immunother Cancer. 2021;9:e002998. https:\/\/doi.org\/10.1136\/jitc-2021-002998.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1425_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1724600819884722","volume":"34","author":"SW Chen","year":"2019","unstructured":"Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, Li YD, Bei JX, Chen WK, Zhang Q. Expression of PD-1\/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int J Biol Markers. 2019;34(4):398\u2013405. https:\/\/doi.org\/10.1177\/1724600819884722.","journal-title":"Int J Biol Markers"},{"issue":"3","key":"1425_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","volume":"23","author":"AT Ruffin","year":"2023","unstructured":"\u2022\u2022 Ruffin AT, Li H, Vujanovic A, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumor microenvironment. Nat Rev Cancer. 2023;23(3):173\u201388. https:\/\/doi.org\/10.1038\/s41568-022-00531-9. An up to date manuscript on the significance of modulating the tumor microenvironment to combat HNSCC.","journal-title":"Nat Rev Cancer"},{"key":"1425_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-030-49270-0-6","volume":"1273","author":"RE Dadey","year":"2020","unstructured":"Dadey RE, Workman CJ, Vignali DA. A regulatory T cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:105\u201334. https:\/\/doi.org\/10.1007\/978-3-030-49270-0-6.","journal-title":"Adv Exp Med Biol"},{"key":"1425_CR36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20:724\u201335. https:\/\/doi.org\/10.1038\/s41590-019-0346-9.","journal-title":"Nat Immunol"},{"key":"1425_CR37","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/bjc.2013.645","volume":"109","author":"HB Jie","year":"2013","unstructured":"Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109:2629\u201335. https:\/\/doi.org\/10.1038\/bjc.2013.645.","journal-title":"Br J Cancer"},{"key":"1425_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.trecan.2018.03.006","volume":"4","author":"RT Santuray","year":"2018","unstructured":"Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer. Trends Cancer. 2018;4:385\u201396. https:\/\/doi.org\/10.1016\/j.trecan.2018.03.006.","journal-title":"Trends Cancer"},{"key":"1425_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-018-0654-5","volume":"20","author":"J Moskovitz","year":"2018","unstructured":"Moskovitz J, Moy J, Ferris RL. Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol Rep. 2018;20:22. https:\/\/doi.org\/10.1007\/s11912-018-0654-5.","journal-title":"Curr Oncol Rep"},{"key":"1425_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","volume":"5","author":"LL Siu","year":"2019","unstructured":"Siu LL, Even C, Mes\u00eda R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Bra\u00f1a I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1\u2013low\/negative recurrent or metastatic HNSCC. JAMA Oncol. 2019;5:195. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4628.","journal-title":"JAMA Oncol"},{"key":"1425_CR41","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","volume":"31","author":"RL Ferris","year":"2020","unstructured":"Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31:942\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.001.","journal-title":"Ann Oncol"},{"key":"1425_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T Van Hall","year":"2019","unstructured":"Van Hall T, Andr\u00e9 P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7:263. https:\/\/doi.org\/10.1186\/s40425-019-0761-3.","journal-title":"J Immunother Cancer"},{"key":"1425_CR43","doi-asserted-by":"publisher","first-page":"v449","DOI":"10.1093\/annonc\/mdy452","volume":"30","author":"R Galot","year":"2019","unstructured":"Galot R, Tourneau CL, Saada-Bouzid E, Daste A, Even C, Debruyne PR, Henry S, Zanetta S, Rutten A, Licitra LF. A phase II study of monalizumab in patients with recurrent\/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). Ann Oncol. 2019;30:v449\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdy452.","journal-title":"Ann Oncol"},{"key":"1425_CR44","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bl\u00e9ry M, Bonnafous C, Gauthier L, Morel A. Anti-NKG2A MAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731-43.e13. https:\/\/doi.org\/10.1016\/j.cell.2018.10.014.","journal-title":"Cell"},{"key":"1425_CR45","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.3390\/ijms23147889","volume":"23","author":"S Ghosh","year":"2022","unstructured":"\u2022\u2022 Ghosh S, Shah PA, Johnson FM. Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma. Int J Mol Sci. 2022;23:7889. https:\/\/doi.org\/10.3390\/ijms23147889. A very interesting update on immuno therapy in HNSCC.","journal-title":"Int J Mol Sci"},{"key":"1425_CR46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25:947\u201353. https:\/\/doi.org\/10.1038\/s41591-019-0421-7.","journal-title":"Nat Med"},{"key":"1425_CR47","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330.","journal-title":"Blood"},{"key":"1425_CR48","doi-asserted-by":"publisher","first-page":"1021609","DOI":"10.3389\/fonc.2022.1021609.eCollection2022","volume":"12","author":"MPS Damasio","year":"2022","unstructured":"\u2022\u2022 Damasio MPS, Nascimento CS, Andrade LM, de Oliveira VL, Calzavara-Silva CE. The role of T cells in head and neck squamous cell carcinoma: from immunity to immunotherapy. Front Oncol. 2022;12:1021609. https:\/\/doi.org\/10.3389\/fonc.2022.1021609.eCollection2022. An overview on the role of immunotherapy, with special interest in CAR-T cells therapy in HNSCC.","journal-title":"Front Oncol"},{"key":"1425_CR49","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1158\/1538-7445.am2019-574","volume":"79","author":"EA Warren","year":"2019","unstructured":"Warren EA, Liu H-C, Porter CE, Liao KS, Hegde M, Yu W, et al. Abstract 574: overexpression of HER2 in head and neck cancer represents a potential target for T cell immunotherapy. Cancer Res. 2019;79:574\u201384. https:\/\/doi.org\/10.1158\/1538-7445.am2019-574.","journal-title":"Cancer Res"},{"key":"1425_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.oraloncology.2018.01.024","volume":"78","author":"YP Park","year":"2018","unstructured":"Park YP, Jin L, Bennett KB, Wang D, Fredenburg KM, Tseng JE, Chang LJ, Huang J, Chan EKL. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. Oral Oncol. 2018;78:145\u201350. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.01.024.","journal-title":"Oral Oncol"},{"key":"1425_CR51","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ccell.2022.10.016","volume":"54","author":"SM Norberg","year":"2021","unstructured":"Norberg SM, Hinrichs CS. Advances in adoptive cell therapy for head and neck cancer. Otolaryngol Clin N Am. 2021;54:761\u20138. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.016.","journal-title":"Otolaryngol Clin N Am"},{"key":"1425_CR52","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1200\/JCO.18.02424","volume":"37","author":"SL Doran","year":"2019","unstructured":"Doran SL, Stevanovic\u00b4 S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenbetg SA, Hinrichs CS. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study. J Clin Oncol. 2019;37:2759\u201368. https:\/\/doi.org\/10.1200\/JCO.18.02424.","journal-title":"J Clin Oncol"},{"key":"1425_CR53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s40425-019-0678-x","volume":"7","author":"B Marcinkowski","year":"2019","unstructured":"Marcinkowski B, Stevanovic\u00b4 S, Helman SR, Norberg SM, Serna C, Jin B, Gkitsas N, Kadakia T, Warner A, Davis JL, Rooper L, Hinrichs CS. Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu lung cancer antigen-1. J Immunother Cancer. 2019;7:229. https:\/\/doi.org\/10.1186\/s40425-019-0678-x.","journal-title":"J Immunother Cancer"},{"key":"1425_CR54","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/1759-7714.13043","volume":"10","author":"Y Bai","year":"2019","unstructured":"Bai Y, Hui P, Du X, Su X. Updates to the antitumor mechanism of oncolytic virus. Thorac cancer. 2019;10:1031\u20135. https:\/\/doi.org\/10.1111\/1759-7714.13043.","journal-title":"Thorac cancer"},{"issue":"1","key":"1425_CR55","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12935-021-02024-5","volume":"21","author":"G Cheng","year":"2021","unstructured":"Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int. 2021;21(1):406. https:\/\/doi.org\/10.1186\/s12935-021-02024-5.","journal-title":"Cancer Cell Int"},{"key":"1425_CR56","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373\u20139. https:\/\/doi.org\/10.1111\/cas.13027.","journal-title":"Cancer Sci"},{"key":"1425_CR57","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","volume":"22","author":"FJ Kohlhapp","year":"2016","unstructured":"Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22:1048\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2667.","journal-title":"Clin Cancer Res"},{"key":"1425_CR58","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12935-021-02024-5","volume":"21","author":"G Cheng","year":"2021","unstructured":"Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int. 2021;21:406. https:\/\/doi.org\/10.1186\/s12935-021-02024-5.","journal-title":"Cancer Cell Int"},{"key":"1425_CR59","doi-asserted-by":"publisher","first-page":"108846","DOI":"10.1016\/j.intimp.2022.108846","volume":"110","author":"Y Huang","year":"2022","unstructured":"Huang Y, Liao J, Liang F, Lin P, Wu S, Ye Y, Gao M, Chen R, Zeng H, Yin X, Jiang Y, Ouyang N, Han P, Huang X. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. Int Immunopharmacol. 2022;110:108846. https:\/\/doi.org\/10.1016\/j.intimp.2022.108846.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1425_CR60","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"\u2022 Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(16)30066-3. An original-and why not pioneering- research regarding pembrolizumab for the treatment of R\/M HNSCC.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1425_CR61","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the nead and neck cancer. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"issue":"14","key":"1425_CR62","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for platinum and cetuximab-refractory head and neck cancer: results from a single-arm phase II study. J Clin Oncol. 2017;35(14):1542\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.70.1524.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1425_CR63","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/JCO.21.02198","volume":"40","author":"B Burtness","year":"2022","unstructured":"Burtness B, Rischin D, Greil R, Souli\u00e8res D, Tahara M, de Castro G, Psyrri A, Brana I, Bast\u00e9 N, Neupane P, Bratland \u00c5, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE 048 Study: subgroup analysis by programmed death ligand -1 combined positive score. J Clin Oncol. 2022;40(21):2321\u201332. https:\/\/doi.org\/10.1200\/JCO.21.02198.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1425_CR64","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1007\/s00204-020-02833-z","volume":"94","author":"H Yamamoto","year":"2020","unstructured":"\u2022 Yamamoto H, Watanabe Y, Maehata T, Imai K, Itoh F. Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. Arch Toxicol. 2020;94(10):3349\u201357. https:\/\/doi.org\/10.1007\/s00204-020-02833-z. A very interesting manuscript elaborating upon the micro satellite instability in cancer.","journal-title":"Arch Toxicol"},{"issue":"12","key":"1425_CR65","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00432-019-02942-y","volume":"145","author":"G Yang","year":"2019","unstructured":"Yang G, Zheng RY, Jin ZS. Correlations between microsatellite instability and the biological behavior of tumors. J Cancer Res Clin Oncol. 2019;145(12):2891\u20139. https:\/\/doi.org\/10.1007\/s00432-019-02942-y.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1425_CR66","doi-asserted-by":"publisher","first-page":"e100147","DOI":"10.1136\/jitc-2019-000147","volume":"8","author":"DM Merino","year":"2020","unstructured":"Merino DM, McShane LM, Fabrizio D, Funari V, Chen S, White JR. Establishing guidelines to harmonize tumor mutational burden: in silico assessment of variation in TMB quantification across diagnostic platforms:phase 1 of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e100147. https:\/\/doi.org\/10.1136\/jitc-2019-000147.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1425_CR67","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncy22174","volume":"5","author":"A Addeo","year":"2019","unstructured":"\u2022 Addeo A, Banna GL, Weiss GJ. Tumor mutation burden: from hopes to doubts. JAMA Oncol. 2019;5(7):934\u20135. https:\/\/doi.org\/10.1002\/cncy22174. A recent manuscript focusing upon tumor mutation burden and analyzing the prons and cons of this parameter.","journal-title":"JAMA Oncol"},{"issue":"25","key":"1425_CR68","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131. https:\/\/doi.org\/10.1056\/NEJMc1713444.","journal-title":"N Engl J Med"},{"issue":"17","key":"1425_CR69","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden high solid tumors. Clin Cancer Res. 2021;27(17):4685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327.","journal-title":"Clin Cancer Res"},{"key":"1425_CR70","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Omo M. Regulatory T cells and immune tolerance. Cell. 2008;133:775\u201387. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009.","journal-title":"Cell"},{"issue":"15","key":"1425_CR71","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1158\/0008-5472.CAN-18-3622","volume":"79","author":"J Castillo","year":"2019","unstructured":"Castillo J, Wu E, Lowe C, Srinivasan S, McCord R, Wagle MC, Jayakar S, Edick MG, Eastham-Anderson J, Liu B, Hutchinson KE, Jones W, Stokes MP, Tarighat SS, Holcomb T, Glibicky A, Romero FA, Magnuson S, Huang SA, Plaks V, Giltnane JM, Lackner MR, Mounir Z. CBP\/p300 drives the differentiation of regulatory T cells through transcriptional and non-transcriptional mechanisms. Cancer Res. 2019;79(15):3916\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3622.","journal-title":"Cancer Res"},{"issue":"4","key":"1425_CR72","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","volume":"17","author":"JA Clara","year":"2020","unstructured":"Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17(4):204\u201332. https:\/\/doi.org\/10.1038\/s41571-019-0293-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"1425_CR73","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-19-3976","volume":"26","author":"K Zhang","year":"2020","unstructured":"Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G, Zhang Y, Zhao X, Zhao Z, Zhao J, Huang M, Huang D, Qi C, Gao C, Cai S, Gu F, Hu Y, Xu C, Wang W, Lou Z, Zhang Y, Liu L. Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC. Clin Cancer Res. 2020;26(14):3649\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3976.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1425_CR74","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/s41467-018-06081-9","volume":"9","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Jiang YY, Xie JJ, Mayakonda A, Hazawa M, Chen L, Xiao JF, Li CQ, Huang ML, Ding LW, Sun QY, Xu L, Kanojia D, Jeitany M, Deng JW, Liao LD, Soukiasian HJ, Berman BP, Hao JJ, Xu LY, Li EM, Wang MR, Bi XG, Lin DC, Koeffler HP. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression. Nat Commun. 2018;9(1):3619. https:\/\/doi.org\/10.1038\/s41467-018-06081-9.","journal-title":"Nat Commun"},{"key":"1425_CR75","doi-asserted-by":"publisher","first-page":"862860","DOI":"10.3389\/fgene.2022.862860","volume":"13","author":"L Zheng","year":"2022","unstructured":"\u2022 Zheng L, Guan Z, Xue M. TGF-\u03b2 signaling pathway-based model to predict the subtype and prognosis of head and neck squamous cell carcinoma. Front Genetics. 2022;13:862860. https:\/\/doi.org\/10.3389\/fgene.2022.862860. A very recent manuscript focusing on the significance of TGF-\u03b2 in the pathogenesis and prognosis of HNSCC.","journal-title":"Front Genetics"},{"issue":"18","key":"1425_CR76","doi-asserted-by":"publisher","first-page":"e162733","DOI":"10.1172\/JCI162733","volume":"132","author":"RB Bell","year":"2022","unstructured":"Bell RB, Gough M, Crittenden R, Young K. Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer. J Clin Invest. 2022;132(18):e162733. https:\/\/doi.org\/10.1172\/JCI162733.","journal-title":"J Clin Invest"},{"issue":"18","key":"1425_CR77","doi-asserted-by":"publisher","first-page":"e161400","DOI":"10.1172\/JCI161400","volume":"132","author":"JM Redman","year":"2022","unstructured":"Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Enhanced neoepitope specific immunity following neoadjuvant PD-L1 and TGF-\u03b2 blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2022;132(18):e161400. https:\/\/doi.org\/10.1172\/JCI161400.","journal-title":"J Clin Invest"},{"issue":"3","key":"1425_CR78","doi-asserted-by":"publisher","first-page":"e003420","DOI":"10.1136\/jitc-2021-003420","volume":"10","author":"AM Starzer","year":"2022","unstructured":"Starzer AM, Heller G, Tomasich E, Melchardt T, Feldmann K, Hatziioannou T, Traint S, Minichsdorfer C, Schwarz-Nemec U, Nackenhorst M, M\u00fcllauer L, Preusser M, Berghoff AS, Fuereder T. DNA methylation profiles differ in responders versus nonresponders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e003420. https:\/\/doi.org\/10.1136\/jitc-2021-003420.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1425_CR79","doi-asserted-by":"publisher","first-page":"e003026","DOI":"10.1136\/jitc-2021-003026","volume":"10","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10(2):e003026. https:\/\/doi.org\/10.1136\/jitc-2021-003026.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"1425_CR80","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. Tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081.","journal-title":"Curr Biol"},{"issue":"1","key":"1425_CR81","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Xia X, Huang LB, An H, Cao M, Kim GD, Chen HN, Zhang WH, Shu Y, Kong X, Ren Z, Li PH, Liu Y, Tang H, Sun R, Li C, Bai B, Jia W, Liu Y, Zhang W, Yang L, Peng Y, Dai L, Hu H, Jiang Y, Hu Y, Zhu J, Jiang H, Li Z, Caulin C, Park J, Xu H. Pan cancer single cell analysis reveals the heterogeneity and plasticity of cancer associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619. https:\/\/doi.org\/10.1038\/s41467-022-34395-2.","journal-title":"Nat Commun"},{"key":"1425_CR82","doi-asserted-by":"publisher","first-page":"857934","DOI":"10.3389\/fimmu.2022.857934","volume":"13","author":"K Du","year":"2022","unstructured":"Du K, Zou J, Wang B, Liu C, Khan M, Xie T, Huang X, Shen P, Tian Y, Yuan Y. A Metabolism-related gene prognostic index bridging metabolic signatures and antitumor immune cycling in head and neck squamous cell carcinoma. Front Immunol. 2022;13:857934. https:\/\/doi.org\/10.3389\/fimmu.2022.857934.","journal-title":"Front Immunol"},{"issue":"16","key":"1425_CR83","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1002\/cam4.4670","volume":"11","author":"W Qiang","year":"2022","unstructured":"Qiang W, Dai Y, Xing X, Sun X. Identification of a metabolic reprogramming-related signature associated with prognosis and immune microenvironment of head and neck squamous cell carcinoma by in silico analysis. Cancer Med. 2022;11(16):3168\u201381. https:\/\/doi.org\/10.1002\/cam4.4670.","journal-title":"Cancer Med"},{"key":"1425_CR84","doi-asserted-by":"publisher","first-page":"781466","DOI":"10.3389\/fimmu.2021.781466","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Wu S, Liu F, Ke D, Wang X, Pan D, Xu W, Zhou L, He W. An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma. Front Immunol. 2021;12:781466. https:\/\/doi.org\/10.3389\/fimmu.2021.781466.","journal-title":"Front Immunol"},{"key":"1425_CR85","doi-asserted-by":"publisher","first-page":"975847","DOI":"10.3389\/fimmu.2022.975847","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Liu Y, Tao B, Xue X, Zhang X, Wang L, Zhong H, Zhang J, Yang S, Jiang Q. NT5E upregulation in head and neck squamous cell carcinoma: a novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment. Front Immunol. 2022;13:975847. https:\/\/doi.org\/10.3389\/fimmu.2022.975847.","journal-title":"Front Immunol"},{"issue":"1","key":"1425_CR86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","volume":"12","author":"N Vallianou","year":"2021","unstructured":"Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules. 2021;12(1):56. https:\/\/doi.org\/10.3390\/biom12010056.","journal-title":"Biomolecules"},{"issue":"3","key":"1425_CR87","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13679-020-00379-w","volume":"9","author":"N Vallianou","year":"2020","unstructured":"Vallianou N, Stratigou T, Christodoulatos GS, Tsigalou C, Dalamaga M. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr Obes Rep. 2020;9(3):179\u201392. https:\/\/doi.org\/10.1007\/s13679-020-00379-w.","journal-title":"Curr Obes Rep"},{"issue":"57","key":"1425_CR88","doi-asserted-by":"publisher","first-page":"97273","DOI":"10.18632\/oncotarget.21921","volume":"8","author":"PK Mukherjee","year":"2017","unstructured":"Mukherjee PK, Wang H, Retuerto M, Zhang H, Burkey B, Ghannoum MA, Eng C. Bacteriome and mycobiome associations in oral tongue cancer. Oncotarget. 2017;8(57):97273\u201389. https:\/\/doi.org\/10.18632\/oncotarget.21921.","journal-title":"Oncotarget"},{"issue":"13","key":"1425_CR89","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.3390\/cancers13133149","volume":"13","author":"N Vallianou","year":"2021","unstructured":"Vallianou N, Kounatidis D, Christodoulatos GS, Panagopoulos F, Karampela I, Dalamaga M. Mycobiome and cancer: what is the evidence? Cancers. 2021;13(13):3149. https:\/\/doi.org\/10.3390\/cancers13133149.","journal-title":"Cancers"},{"issue":"3","key":"1425_CR90","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11912-022-01352-7","volume":"25","author":"K Dorobisz","year":"2023","unstructured":"Dorobisz K, Dorobisz T, Zdonski T. The microbiome\u2019s influence on head and neck cancer. Curr Oncology Rep. 2023;25(3):163\u201371. https:\/\/doi.org\/10.1007\/s11912-022-01352-7.","journal-title":"Curr Oncology Rep"},{"issue":"6371","key":"1425_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondrag\u00f3n L, Jacquelot N, Qu B, Ferrere G, Cl\u00e9menson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryfel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome infuences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"key":"1425_CR92","doi-asserted-by":"publisher","first-page":"15384","DOI":"10.3390\/ijms232315384","volume":"23","author":"PG Meliante","year":"2022","unstructured":"Meliante PG, Barbato C, Zoccali F, Ralli M, Greco A, de Vincentiis M, Colizza A, Petrella C, Ferraguti G, Minni A. Programmed cell death-ligand 1 in head and neck squamous cell carcinoma: molecular insights, preclinical and clinical data, and therapies. Int J Mol Sci. 2022;23:15384. https:\/\/doi.org\/10.3390\/ijms232315384.","journal-title":"Int J Mol Sci"},{"key":"1425_CR93","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, Psyrri A, Bast\u00e9 N, Neupane P, Bratland A, Fuereder T, Hughes BGM, Mes\u00eda R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonz\u00e1lez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"1425_CR94","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"\u2022\u2022 Mody MD, Rocco JW, Yam SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398:2289\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(21)01550-6. An excellent review on the incidence,\naetiologies and treatment modalities regarding head and neck cancer.","journal-title":"Lancet"},{"key":"1425_CR95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.metabol.2018.11.007","volume":"91","author":"R Emfietzoglou","year":"2019","unstructured":"Emfietzoglou R, Spyrou N, Mantzoros CS, Dalamaga M. Could the endocrine disruptor bisphenol-A be implicated in the pathogenesis of oral and oropharyngeal cancer? Metabolic Consider Future Direct Metabol. 2019;91:61\u20139. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.007.","journal-title":"Metabolic Consider Future Direct Metabol"},{"key":"1425_CR96","doi-asserted-by":"publisher","first-page":"705096","DOI":"10.3389\/fimmu.2021.705096","volume":"12","author":"A Botticelli","year":"2012","unstructured":"Botticelli A, Cirillo A, Strigari L, Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Della Rocca C, D\u2019Amati G, Polimeni A, Nuti M, Merlano MC, Mezi S, Marchetti P. Anti\u2013PD-1 and anti\u2013PD-L1 in head and neck cancer: a network meta-analysis. Front Immunol. 2012;12:705096. https:\/\/doi.org\/10.3389\/fimmu.2021.705096.","journal-title":"Front Immunol"},{"key":"1425_CR97","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/cas.14784","volume":"112","author":"H Shibata","year":"2021","unstructured":"Shibata H, Zhou L, Xu N, Egloff AM, Uppaluri R. Personalized cancer vaccination in head and neck cancer. Cancer Sci. 2021;112:978\u201388.","journal-title":"Cancer Sci"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01425-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T04:59:18Z","timestamp":1688619558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01425-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01425-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"19 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and Human Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}